BIONTECH SE-ADR (BNTX) Stock Price, Quote, News and Overview
NASDAQ:BNTX - Nasdaq - US09075V1026 - ADR - Currency: USD
BNTX Quote, Performance and Key Statistics
110.83
-3.94 (-3.43%)
The current stock price of BNTX is 110.83 USD. In the past month the price decreased by -9.44%. In the past year, price increased by 21.43%.
BNTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.83 | 372.42B | ||
| AMGN | AMGEN INC | 16.04 | 170.67B | ||
| GILD | GILEAD SCIENCES INC | 25.17 | 144.59B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1674.9 | 124.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.3 | 76.35B | ||
| ARGX | ARGENX SE - ADR | 238.59 | 37.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.00B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.42B | ||
| BIIB | BIOGEN INC | 8.95 | 21.47B | ||
| NTRA | NATERA INC | N/A | 18.68B | ||
| GMAB | GENMAB A/S -SP ADR | 24.96 | 15.06B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 14.00B |
Related stock screener links
About BNTX
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ 55131 DE
CEO: Ugur Sahin
Employees: 6133
Company Website: https://www.biontech.com/
Investor Relations: https://investors.biontech.de/
Phone: 4949613190840
BIONTECH SE-ADR / BNTX FAQ
What is the stock price of BIONTECH SE-ADR today?
The current stock price of BNTX is 110.83 USD. The price decreased by -3.43% in the last trading session.
What is the ticker symbol for BIONTECH SE-ADR stock?
The exchange symbol of BIONTECH SE-ADR is BNTX and it is listed on the Nasdaq exchange.
On which exchange is BNTX stock listed?
BNTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIONTECH SE-ADR stock?
27 analysts have analysed BNTX and the average price target is 142.02 USD. This implies a price increase of 28.14% is expected in the next year compared to the current price of 110.83. Check the BIONTECH SE-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIONTECH SE-ADR worth?
BIONTECH SE-ADR (BNTX) has a market capitalization of 26.57B USD. This makes BNTX a Large Cap stock.
How many employees does BIONTECH SE-ADR have?
BIONTECH SE-ADR (BNTX) currently has 6133 employees.
What are the support and resistance levels for BIONTECH SE-ADR (BNTX) stock?
BIONTECH SE-ADR (BNTX) has a support level at 110.82 and a resistance level at 112.28. Check the full technical report for a detailed analysis of BNTX support and resistance levels.
Is BIONTECH SE-ADR (BNTX) expected to grow?
The Revenue of BIONTECH SE-ADR (BNTX) is expected to decline by -38.23% in the next year. Check the estimates tab for more information on the BNTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIONTECH SE-ADR (BNTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BNTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BNTX, evaluating the profitability, health, valuation and growth aspects
- BIONTECH SE-ADR (BNTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIONTECH SE-ADR (BNTX) Sales and EPS estimates to see what analysts future expectations are.
- BIONTECH SE-ADR (BNTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIONTECH SE-ADR (BNTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIONTECH SE-ADR (BNTX) Stock Chart to make your own analysis
- BIONTECH SE-ADR (BNTX) Latest news and press-releases to stay up to date.
Does BIONTECH SE-ADR (BNTX) stock pay dividends?
BNTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIONTECH SE-ADR (BNTX)?
BIONTECH SE-ADR (BNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.1).
What is the Short Interest ratio of BIONTECH SE-ADR (BNTX) stock?
The outstanding short interest for BIONTECH SE-ADR (BNTX) is 3.28% of its float. Check the ownership tab for more information on the BNTX short interest.
BNTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BNTX. When comparing the yearly performance of all stocks, BNTX is one of the better performing stocks in the market, outperforming 79.34% of all stocks.
BNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BNTX. BNTX has an excellent financial health rating, but there are some minor concerns on its profitability.
BNTX Financial Highlights
Over the last trailing twelve months BNTX reported a non-GAAP Earnings per Share(EPS) of -2.1. The EPS decreased by -117.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.08% | ||
| ROE | -2.44% | ||
| Debt/Equity | 0.01 |
BNTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to BNTX. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -185.35% and a revenue growth -38.23% for BNTX